Friday, July 20, 2018 Daily Archives

Pluristem and Thermo Fisher Look to Plug Gaps in Cell Therapy Manufacture

by

Pluristem and Thermo Fisher will work to address the lack of technologies available to cell therapy manufacturers for the cultivation and processing of allogeneic products. “There is a lack of technologies for the cultivation and processing of allogeneic products whose potential is high scale production,†Yaky Yanay, president and co-CEO of Pluristem Therapeutics told BioProcess Insider. “Some of the gaps are in the technology itself, some are in the quality or the availability of raw materials.†To minimize some of…

July 20, 2018

Univercells $19m Booster Shot to Help Disrupt Vaccine Industry

by

Traditional vaccine makers have limited incentive to invest in new technologies and processes says Univercells, which hopes to advance its own viral vaccines produced in micro-facilities. Univercells has raised €16 million (US$18.7 million) of funding in a Series B financing round led by Global Health Investment Fund. Some of the capital will be used to increase the impact of its proprietary viral platform through the expansion of its portfolio. “Following the platform proof of concept, with its sIPV development program…

July 20, 2018

‘Dramatic’ Gene Therapy Demand Drives Viral Vector Delays

by

Some gene therapy developers are waiting more than a year for viral vectors due to the shortage in third-party services, says European CDMO Yposkesi. French contract development and manufacturing organization (CDMO) Yposkesi claims to have the largest industrial platform for the GMP manufacture of viral vectors for gene therapies in Europe. The firm has four independent production suites and two fill & finish suites, with current capacity of 35 batches per year. And now the manufacturer is set to grow…

July 20, 2018